SCHEMBL4716180

SCHEMBL4716180

COc1cc(C(C)O)cc2c1OCCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.51
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 2/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP3A4 P08684 2/20 0.38
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ACHE P22303 1/20 0.35
CTNNB1 P35222 1/20 0.35
WNT3A P56704 1/20 0.35
AOC3 Q16853 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34
SOAT1 P35610 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4713032 0.87 CYP3A4 (0.51) ALDH1A1POLBCYP3A4SMN1; SMN2ACHE
SCHEMBL13085692 0.87 PLK1 (0.50) PLK1ALDH1A1KDM4EPOLBTDP1
SCHEMBL13085629 0.81 PLK1 (0.44) PLK1ALDH1A1KDM4EPOLBTDP1
SCHEMBL14040929 0.77 CTNNB1 (0.34) ALDH1A1PTGS1PTGS2SMN1; SMN2ACHE
SCHEMBL11999824 0.74 PLK1 (0.54) PLK1ALDH1A1KDM4EPOLBTDP1
SCHEMBL12781853 0.73 CYP3A4 (0.54) ALDH1A1POLBLMNACYP3A4SMN1; SMN2
SCHEMBL5309009 0.73 PLK1 (0.50) PLK1ALDH1A1KDM4EPOLBTDP1
SCHEMBL12184928 0.73 PLK1 (0.53) PLK1ALDH1A1KDM4EPOLBTDP1
SCHEMBL2800254 0.72 CYP3A4 (0.53) PLK1ALDH1A1KDM4EPOLBTDP1
SCHEMBL4715766 0.71 PLK1 (0.71) PLK1ALDH1A1KDM4EPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373257-B9 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES VERTEX PHARMA (US) 2008-10-15 EP disclosed
EP-1373257-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES VERTEX PHARMA (US) 2007-11-28 EP disclosed
US-6949544-B2 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-09-27 US disclosed
US-20030087922-A1 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087922-A1 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases CDK2, LCK, CDK5 PLK1 215/4885ALDH1A1 4705/4885KDM4E 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.